Investors are increasingly eyeing artificial intelligence's expansion into drug discovery as the next big opportunity in healthcare.
According to an article published on MSN, the next wave of medical AI could "mint more millionaires than the first" — suggesting that companies positioned at the intersection of AI and biotech may deliver outsized returns for shareholders.
The piece points to two companies as potential winners in this shift: pharmaceutical giant Eli Lilly and Twist Bioscience, a firm focused on synthetic biology. The framing is that AI's earlier gains, concentrated in areas like computing hardware and software, may be followed by a healthcare-driven phase where drug developers and biotech infrastructure providers benefit.
For everyday readers, the appeal is straightforward. AI tools promise to speed up the slow, expensive process of finding and testing new medicines — work that has traditionally taken years and billions of dollars. If those tools deliver, the companies that own the data, the lab technology, and the drug pipelines stand to gain.
It's worth keeping the source in perspective: this is an investment-focused outlook naming specific stocks to consider, not a confirmed account of breakthroughs or financial results. Stock predictions are inherently uncertain, and the article frames these names as opportunities rather than guarantees.
Why it matters: the story signals that Wall Street's AI enthusiasm is broadening beyond tech into medicine, where the stakes — both financial and human — are especially high.